Friday, 16 October 2026European Markets

THALES And PERRIER (GERARD) Have A High Dividend Yield And Return On Equity In The Industrials Sector.

Loading stream...

(vianews) - thales (ho.pa) is among this list of stock assets with the highest dividend rate and return on equity on the industrials sector.

financial asset price forward dividend yield return on equity
thales (ho.pa) €129.10 2.1% 15.91%
perrier (gerard) (perr.pa) €109.50 1.95% 16.51%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. thales (ho.pa)

2.1% forward dividend yield and 15.91% return on equity

thales s.a. provides various solutions for civilian and military customers in the defence and security, aerospace and space, digital identity and security, and transport markets worldwide. it operates through aerospace, defence & security, digital identity & security, and ground transportation systems business segments. the company offers communications, command, and control systems; mission services and support; protection and mission/combat systems; surveillance, detection, and intelligence systems; training and simulation solutions for air, land, naval, and joint forces; and digital identity and security solutions. it also provides air traffic management solutions; flight decks and avionics equipment and functions; in-flight entertainment and connectivity systems and services; electrical systems; aerospace trading solutions; navigation solutions; support and services for avionics equipment; and connectivity solutions. in addition, the company designs, operates, and delivers satellite-based systems for telecommunications, navigation, earth observation, environmental management, exploration, and science and orbital infrastructures; signaling, communications and supervision, and fare collection management systems and related services; cybersecurity and railway digitalization systems; and main line rail, and urban and intermodal mobility solutions. further, it provides solutions for various markets and applications, including radiology, radio frequency, microwave sources, training and simulation solutions, lasers, and microelectronics solutions for science, industry, space, defense, automotive, railways, and energy conversion platforms. the company was formerly known as thomson-csf and changed its name to thales s.a. in 2000. thales s.a. was founded in 1893 and is headquartered in courbevoie, france.

earnings per share

as for profitability, thales has a trailing twelve months eps of €5.23.

pe ratio

thales has a trailing twelve months price to earnings ratio of 24.68. meaning, the purchaser of the share is investing €24.68 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.91%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on may 23, 2023, the estimated forward annual dividend rate is 2.94 and the estimated forward annual dividend yield is 2.1%.

more news about thales.

2. perrier (gerard) (perr.pa)

1.95% forward dividend yield and 16.51% return on equity

gérard perrier industrie s.a. engages in design, manufacture, installation, and maintainence of electrical, electronic, automation, and instrumentation equipment in france and internationally. it engages in the engineering, installation, and maintenance of hv/lv distribution networks, electric drive systems, low current systems, lighting products, electric boxes, cabinets, and modules. the company is also involved in the study, manufacture, and installation of electronic boards, modules, sub-assemblies, assemblies, man-machine interfaces for on-board systems, built-in automated and electronic systems, switched-mode power supplies and converters for on-board systems, and variators and engine control systems; study, engineering, and maintenance of automation projects; and design, analysis, and programming of techniques for automation supervision and mes systems. in addition, it manufactures sub-assemblies, such as electronic, electro-technical, assembly of mechanical, and fluid and pneumatic modules; implements engineering projects in the oil and gas, nuclear, and military sectors; and technical assistance for various businesses, such as mechanics, valves, boiler-making, civil engineering, and non-destructive testing. the company was founded in 1967 and is headquartered in lyon, france. gérard perrier industrie s.a. operates as a subsidiary of amperra.

earnings per share

as for profitability, perrier (gerard) has a trailing twelve months eps of €4.46.

pe ratio

perrier (gerard) has a trailing twelve months price to earnings ratio of 24.55. meaning, the purchaser of the share is investing €24.55 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.51%.

moving average

perrier (gerard)'s worth is higher than its 50-day moving average of €102.15 and way above its 200-day moving average of €95.57.

more news about perrier (gerard).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com